MediLink Therapeutics (Suzhou) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Active:1

Completed:0

Trial Phases

4 Phases

Phase 1:6

Phase 2:3

Phase 3:2

+1 more phases

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 1

6 (46.2%)

Phase 2

3 (23.1%)

Not Applicable

2 (15.4%)

Phase 3

2 (15.4%)

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not Applicable

Recruiting

Conditions: Advanced Solid Tumors
Breast Cancer
Non Small Cell Lung Cancer

Interventions: Drug: YL202 for injection; Toripalimab injection
Drug: YL202 for injection; Furmonertinib Mesilate Tablets

First Posted Date: 2025-09-12

Last Posted Date: 2025-09-12

Lead Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Target Recruit Count: 414

Registration Number: NCT07169994

Locations: 🇨🇳
Anhui Provincial Hospital(The First Affiliated Hospital of Ustc), Hefei, Anhui, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 16 locations

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: YL217

First Posted Date: 2025-03-05

Last Posted Date: 2025-07-11

Lead Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Target Recruit Count: 220

Registration Number: NCT06859762

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

and more 10 locations